BJA Open (Mar 2022)
False-positive and false-negative risks for individual multicentre trials in critical care
Abstract
Background: In medical research, null hypothesis significance testing (NHST) is the dominant framework for statistical inference. NHST involves calculating P-values and confidence intervals to quantify the evidence against the null hypothesis of no effect. However, P-values and confidence intervals cannot tell us the probability that the hypothesis is true. In contrast, false-positive risk (FPR) and false-negative risk (FNR) are post-test probabilities concerning the truth of the hypothesis, that is to say, the probability a real effect exists. Methods: We calculated the FPR or FNR for 53 individual multicentre trials in critical care based on a pretest probability of 0.5 that the hypothesis was true. Results: For trials reporting statistical significance, the FPR varied between 0.1% and 57.6%. For trials reporting non-significance, the FNR varied between 1.7% and 36.9%. Twenty-six of 47 trials (55.3%) reporting non-significance provided strong or very strong evidence in favour of the null hypothesis; the remaining trials provided limited evidence. There was no obvious relationship between the P-value and the FNR. Conclusions: The FPR and FNR showed marked variability, indicating that the probability of a real or absent treatment effect differed substantially between trials. Only one trial reporting statistical significance provided convincing evidence of a real treatment effect, and nearly half of all trials reporting non-significance provided limited evidence for the absence of a treatment effect. Our findings suggest that the quality of evidence from multicentre trials in critical care is highly variable.
